◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Home › All stocks › I › IART

Integra LifeSciences Holdings (IART) Financial History

20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

HEALTHCARE · MEDICAL DEVICES · DATA UPDATED 2026-09-16

Integra LifeSciences Holdings (IART) operates in the MEDICAL DEVICES industry and is headquartered in Princeton, United States with about 4,427 employees. Its market capitalization is roughly $1 billion. In the fiscal year ended 2025-12-31, IART reported $1.6B in revenue and ($516M) in net income.

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical, ear, nose, throat, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates through Codman Specialty Surgical and Tissue Technologies segments.

Interactive charts & full statements → Open the IART valuation workbench →

IART Revenue & Earnings History — Annual Income Statement

Income statement	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Total Revenue	$1.6B	$1.6B	$1.6B	$1.5B	$1.6B	$1.5B	$1.4B	$1.5B	$1.5B	$1.2B	$992M	$883M	$928M	$836M	$831M	$780M	$732M	$682M	$655M	$550M	$419M
Gross Profit	$885M	$845M	$882M	$885M	$970M	$945M	$851M	$953M	$901M	$753M	$643M	$556M	$576M	$502M	$516M	$481M	$464M	$438M	$402M	$336M	$251M
Gross Margin %	53.7%	51.7%	54.8%	57.4%	62.3%	61.2%	62.0%	62.8%	61.2%	63.3%	64.8%	63.0%	62.0%	60.1%	62.2%	61.7%	63.4%	64.1%	61.4%	61.0%	59.9%
Operating Income (EBIT)	$656M	$68M	$28M	$112M	$239M	$197M	$151M	$94M	$111M	$45M	$115M	$80M	$66M	($4M)	$74M	$55M	$99M	$98M	$47M	$67M	$59M
Operating Margin %	39.8%	4.2%	1.8%	7.2%	15.3%	12.8%	11.0%	6.2%	7.5%	3.8%	11.6%	9.0%	7.1%	-0.4%	8.9%	7.0%	13.5%	14.3%	7.2%	12.2%	14.0%
Net Income	($7M)	($516M)	($7M)	$68M	$181M	$169M	$134M	$50M	$61M	$65M	$75M	($4M)	$34M	($17M)	$41M	$28M	$66M	$51M	$35M	$33M	$29M
Net Margin %	-0.4%	-31.6%	-0.4%	4.4%	11.6%	11.0%	9.8%	3.3%	4.1%	5.5%	7.5%	-0.4%	3.7%	-2.0%	5.0%	3.6%	9.0%	7.5%	5.3%	6.1%	7.0%
EBITDA	$249M	($326M)	$193M	$256M	$385M	$366M	$268M	$224M	$241M	$135M	$232M	$196M	$172M	$40M	$116M	$106M	$140M	$136M	$79M	$67M	$59M
Earnings Per Share (EPS)	$-0.10	$-6.73	$-0.09	$0.84	$2.16	$1.98	$1.57	$0.58	$0.72	$0.82	$0.94	$-0.05	$0.52	$-0.29	$0.72	$0.47	$1.09	$0.87	$0.62	$0.57	$0.45
Shares Outstanding (M)	78M	77M	77M	80M	84M	85M	85M	86M	84M	79M	79M	74M	66M	58M	57M	59M	60M	59M	57M	59M	65M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

IART Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Total Revenue	$419M	$392M	$435M	$402M	$416M	$383M	$443M	$381M
Gross Profit	$220M	$224M	$215M	$226M	$209M	$194M	$249M	$200M
Gross Margin %	52.5%	57.2%	49.5%	56.2%	50.4%	50.8%	56.3%	52.6%
Operating Income (EBIT)	$19M	$40M	$556M	$40M	($513M)	($15M)	$36M	($8M)
Operating Margin %	4.6%	10.2%	127.9%	10.0%	-123.4%	-4.0%	8.1%	-2.1%
Net Income	$4M	($5M)	($2M)	($5M)	($484M)	($25M)	$19M	($11M)
Net Margin %	1.1%	-1.2%	-0.4%	-1.3%	-116.5%	-6.6%	4.4%	-2.8%
EBITDA	$66M	$63M	$66M	$54M	($472M)	$26M	$79M	$35M
Earnings Per Share (EPS)	$0.06	$-0.06	$-0.02	$-0.07	$-6.33	$-0.33	$0.25	$-0.14
Shares Outstanding (M)	78M	77M	77M	77M	76M	76M	77M	76M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

IART Free Cash Flow History

Cash flow	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Cash from Operations (CFO)	$85M	$50M	$129M	$140M	$264M	$312M	$204M	$231M	$200M	$115M	$116M	$94M	$79M	$53M	$59M	$104M	$106M	$143M	$73M	$47M	$72M
Capital Expenditures (CapEx)	$76M	$96M	$104M	$67M	$47M	$48M	$64M	$135M	$78M	$44M	$47M	$33M	$42M	$48M	$69M	$38M	$37M	$28M	$13M	$23M	$12M
Free Cash Flow (FCF)	$9M	($45M)	$25M	$73M	$217M	$264M	$140M	$97M	$122M	$71M	$69M	$61M	$37M	$5M	($10M)	$66M	$68M	$116M	$59M	$24M	$60M
FCF Margin %	0.5%	-2.8%	1.6%	4.7%	14.0%	17.1%	10.2%	6.4%	8.3%	6.0%	7.0%	6.9%	4.0%	0.7%	-1.2%	8.5%	9.3%	17.0%	9.0%	4.4%	14.3%
Dividends Paid	—	—	—	$93M	$5M	$2M	$45M	$0M	—	$0M	$0M	$0M	$0M	$0M	$0M	$379M	$0M	—	$422M	$348M	—

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

IART Quarterly Free Cash Flow — Last 8 Quarters

Quarterly cash flow	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Cash from Operations (CFO)	$23M	$10M	$12M	$41M	$9M	($11M)	$51M	$22M
Capital Expenditures (CapEx)	$15M	$15M	$31M	$15M	$20M	$29M	$40M	$30M
Free Cash Flow (FCF)	$8M	($5M)	($20M)	$26M	($11M)	($40M)	$11M	($7M)
FCF Margin %	1.9%	-1.3%	-4.5%	6.4%	-2.7%	-10.5%	2.5%	-1.9%

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

IART Balance Sheet History

Balance sheet	2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Total Assets	$3.6B	$3.6B	$4.0B	$3.8B	$3.9B	$3.8B	$3.6B	$3.3B	$3.1B	$3.2B	$1.8B	$1.8B	$1.6B	$1.2B	$1.2B	$1.1B	$1.0B	$940M	$1.0B	$818M	$614M
Cash & Cash Equivalents	$214M	$235M	$246M	$276M	$457M	$513M	$470M	$199M	$139M	$175M	$102M	$48M	$72M	$121M	$97M	$101M	$129M	$72M	$184M	$57M	$23M
Total Liabilities	$2.5B	$2.6B	$2.5B	$2.2B	$2.1B	$2.1B	$2.1B	$1.9B	$1.7B	$2.2B	$968M	$1.0B	$874M	$526M	$646M	$651M	$517M	$495M	$684M	$558M	$317M
Total Debt (Short + Long-Term)	$1.9B	$1.9B	$1.8B	$1.5B	$1.4B	$1.5B	$1.6B	$1.3B	$1.2B	$1.8B	$1.3B	$715M	$630M	$394M	$520M	$532M	$403M	$386M	$590M	$450M	$220M
Total Shareholders' Equity	$1.1B	$1.0B	$1.5B	$1.6B	$1.8B	$1.7B	$1.5B	$1.4B	$1.4B	$962M	$840M	$751M	$704M	$670M	$518M	$493M	$500M	$445M	$350M	$260M	$296M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive IART viewer.

Other Companies in MEDICAL DEVICES

ESTA · Establishment Labs Holdings Inc — $2 billion
NVCR · Novocure Ltd — $2 billion
ATEC · Alphatec Holdings Inc — $2 billion
CNMD · CONMED Corporation — $1 billion
TNDM · Tandem Diabetes Care Inc — $1 billion
AORT · Artivion Inc — $1 billion
PRCT · Procept Biorobotics Corp — $1 billion
LMRI · Lumexa Imaging Holdings, Inc. Common Stock — $1 billion

← IAPR All “I” companies IASH →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.